We scan new podcasts and send you the top 5 insights daily.
In relapsed CLL, venetoclax-rituximab yields a median progression-free survival of under 40 months following covalent BTK inhibitor failure, compared to 54 months in historical chemoimmunotherapy trials. Intensifying therapy with a pirtobrutinib triplet (PVR) cuts progression risk by nearly half in this aggressive post-covalent BTKI population.
While pirtobrutinib works after covalent BTK inhibitors, no data shows covalent inhibitors work after pirtobrutinib failure. This uncertainty about future options makes clinicians cautious about using it as an initial therapy, especially for younger CLL patients who will need multiple treatments over their lifetime.
Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.
When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.
In CLL patients with significant nodal bulk, BTK inhibitors are preferred over venetoclax-obinutuzumab. Data shows large disease bulk is a significant independent predictor of shorter progression-free survival with the venetoclax doublet (Hazard Ratio ~1.8), likely due to stromal support signals in bulky nodes.
Despite strong single-agent trial results, experts believe the field is shifting away from continuous monotherapy. The most significant future impact for pirtobrutinib will likely be as a backbone of fixed-duration combination therapies with drugs like venetoclax, aiming for deeper remissions without indefinite treatment.
Data from the BRUIN CLL-322 trial shows that adding pirtobrutinib to venetoclax-rituximab (PVR) significantly improves progression-free survival for CLL patients who have previously been treated with a BTK inhibitor. This establishes the triplet as a new, potent, and likely future standard regimen for this high-need population.
While pirtobrutinib was already used off-label per NCCN guidelines, its official FDA approval provides a government-sanctioned alternative, forcing a direct decision between it and a venetoclax-based regimen for patients relapsing on a prior BTK inhibitor.
Abstract data from the BRUIN CLL-322 trial reveals that adding pirtobrutinib to a venetoclax-rituximab backbone provides a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously treated CLL, without a substantial increase in toxicity.
For high-risk CLL patients who progress after both covalent BTK inhibitors and venetoclax, pirtobrutinib is not just the next line of therapy. It is strategically used to achieve disease control, creating a window to prepare the patient for a more definitive and potentially curative CAR-T cell therapy.
When a CLL patient progresses on a BTK inhibitor, experts may overlap it with venetoclax for a month or two. This practical, off-label approach leverages potential synergism and provides disease control while the venetoclax dose is being ramped up, before discontinuing the failing BTK inhibitor.